| |
|
|
|
Novabay Pharmaceuticals  
|
|
2.55 0.02 (0.01%) |
05-25 16:00 |
|
Open: |
2.54 |
Pre close: |
2.53 |
Target:
|
3.55
|
|
High: |
2.55 |
Low: |
2.5 |
Resistance:
|
3.04
3.40
|
|
Volume: |
1,734 |
Market Cap: |
44M |
Support:
|
2.45
2.04
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.68
 |
MACD |
MACD(12,26):
|
-0.16 |
|
MA(20): |
2.93 |
Signal(12,26,9): |
-0.12 |
|
MA(100): |
3.36 |
Stochastic Oscillator |
%K(14,3):
|
7.33 |
|
MA(250): |
3.77 |
%D(3): |
15.30 |
|
Average Volume(K) |
3-Month: |
581
|
52-Week |
High:
|
5.00 |
|
10-Days: |
573 |
Low: |
2.25 |
|
RSI |
RSI(14):
|
32.89  |
Change(%): |
-1.9 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.390 |
Return on Equity (ttm) |
-152.7 |
Shares Out. (M) |
17.09 |
|
EPS Est. Current Year |
-0.470 |
Return on Assets (ttm) |
-58.2 |
Shares Float (M) |
15.31 |
|
EPS Est. Next Year |
-0.090 |
PEG Ratio |
0.00 |
% Held by Insiders |
10.40 |
|
EPS Est. Next Quarter |
-0.030 |
Qtrly Rev. Growth |
54.9 |
% Held by Institutions |
0.70 |
|
Forward EPS |
-0.170 |
Gross Profit (p.s.) |
0.409 |
Shares Short (K) |
139 |
|
Book Value (p.s.) |
19.760 |
EBITDA (p.s.) |
-0.228 |
P/E |
-6.54 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.13 |
|
Profit Margin |
-23.35 |
Operating Cash Flow
(M) |
-6.27 |
P/S |
36621428.00 |
|
Operating Margin |
-40.10 |
Levered Free Cash Flow
(M) |
-2.29 |
P/CF |
-6.95 |
|
|
|
|
|
|
